The company has not filed an annual or quarterly report since its 20-F, filed Mar 29, 2017. Its latest SEC filing is a SC 13G/A from Feb 14, 2018.
20-F, filed Mar 29, 2017
The sections below describe the company as of the latest annual report.
Develops drug-and-device treatment candidates for Parkinson’s disease and cognition disorders, using under-skin pumps or skin patches to deliver medicines continuously.
20-F, filed Mar 29, 2017
The planned treatments target patients with moderate or severe Parkinson’s disease and people with cognition disorders associated with central nervous system diseases. If approved, NeuroDerm plans to work with pharmaceutical companies and other strategic partners to commercialize them.
20-F, filed Mar 29, 2017
Competes with Impax Laboratories, XenoPort, Intec Pharma, Depomed, Synagile, Abbvie, Acorda Therapeutics, Sunovion, Britannia Pharmaceuticals, and U.S. World Med
20-F, filed Mar 29, 2017Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products, treatments or procedures…View ↗
Loading...
